Small Molecule Synthesis in support of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

Amendment 0001: The purpose of this amendment is to answer questions received from potential offerors and update the email addresses referenced in the Instructions to Offerors for receipt of proposals. The closing date and time remain unchanged. Refer to attached document for copy of amendment. -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has a requirement for an IDIQ contract that provides for the synthesis of 350-450 novel small molecule inhibitor analogs, including nucleoside analogs, for a five (5) year ordering period. This is a combined synopsis/solicitation for commercial services prepared in accordance with FAR 12.6, Streamlined Procedures for Evaluation and Solicitation for Commercial Items, as supplemented with additional information included in this notice and FAR 13, Simplified Acquisition Procedures. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number is W81XWH22R0084. The solicitation is issued as a Request for Proposal (RFP). Provisions and clauses in effect through Federal Acquisition Circular 2022-06 are incorporated. It is the contractors responsibility to be familiar with the applicable clauses and provisions. The clause may be access in full text at: https://www.acquisition.gov/. The associated North American Industrial Classification System (NAICS) code for this procurement is 621511, with a small business size standard of $35M. This action is set-aside 100% for small businesses.